Clinical Cases in Tropical Medicine E-Book
eBook - ePub

Clinical Cases in Tropical Medicine E-Book

Camilla Rothe

Buch teilen
  1. 190 Seiten
  2. English
  3. ePUB (handyfreundlich)
  4. Über iOS und Android verfügbar
eBook - ePub

Clinical Cases in Tropical Medicine E-Book

Camilla Rothe

Angaben zum Buch
Buchvorschau
Inhaltsverzeichnis
Quellenangaben

Über dieses Buch

Using an easily accessible, highly templated format, Clinical Cases in Tropical Medicine, 2nd Edition, provides more than 100 realistic scenarios for tropical infectious diseases. Full-color photographs and maps, a convenient question-and-answer presentation, and succinct summary boxes help you identify and understand the tropical diseases you're likely to encounter. This up-to-date 2nd Edition is an excellent resource and study tool for infectious diseases fellows, doctors preparing for exams in tropical medicine, primary care doctors with patients who are global travelers, and global health nurses and practitioners alike.

  • Offers realistic scenarios for encountering patients in rural, resource-poor settings, presenting cases as "unknowns, " just as in a real clinic or emergency situation.
  • Covers newly emerging diseases such as Zika virus, severe fever with thrombocytopenia syndrome (SFTS), and knowlesi malaria.
  • Features topics in migrant medicine of particular importance to clinicians in non-tropical countries, including louse-borne-relapsing fever, spinal brucellosis, and hyperreactive malarial splenomegaly.
  • Includes "classic" tropical diseases such as African trypanosomiasis, chagas, leprosy, and yaws.
  • Reflects the use of novel diagnostics used in resource-poor settings, as well as developing drug resistance in relevant cases.
  • Provides a useful index and map that organize cases geographically, for a targeted approach to study.
  • Serves as a companion to Manson's Tropical Diseases, with a reading list at the end of each case referring to the corresponding chapter in the larger text.

Häufig gestellte Fragen

Wie kann ich mein Abo kündigen?
Gehe einfach zum Kontobereich in den Einstellungen und klicke auf „Abo kündigen“ – ganz einfach. Nachdem du gekündigt hast, bleibt deine Mitgliedschaft für den verbleibenden Abozeitraum, den du bereits bezahlt hast, aktiv. Mehr Informationen hier.
(Wie) Kann ich Bücher herunterladen?
Derzeit stehen all unsere auf Mobilgeräte reagierenden ePub-Bücher zum Download über die App zur Verfügung. Die meisten unserer PDFs stehen ebenfalls zum Download bereit; wir arbeiten daran, auch die übrigen PDFs zum Download anzubieten, bei denen dies aktuell noch nicht möglich ist. Weitere Informationen hier.
Welcher Unterschied besteht bei den Preisen zwischen den Aboplänen?
Mit beiden Aboplänen erhältst du vollen Zugang zur Bibliothek und allen Funktionen von Perlego. Die einzigen Unterschiede bestehen im Preis und dem Abozeitraum: Mit dem Jahresabo sparst du auf 12 Monate gerechnet im Vergleich zum Monatsabo rund 30 %.
Was ist Perlego?
Wir sind ein Online-Abodienst für Lehrbücher, bei dem du für weniger als den Preis eines einzelnen Buches pro Monat Zugang zu einer ganzen Online-Bibliothek erhältst. Mit über 1 Million Büchern zu über 1.000 verschiedenen Themen haben wir bestimmt alles, was du brauchst! Weitere Informationen hier.
Unterstützt Perlego Text-zu-Sprache?
Achte auf das Symbol zum Vorlesen in deinem nächsten Buch, um zu sehen, ob du es dir auch anhören kannst. Bei diesem Tool wird dir Text laut vorgelesen, wobei der Text beim Vorlesen auch grafisch hervorgehoben wird. Du kannst das Vorlesen jederzeit anhalten, beschleunigen und verlangsamen. Weitere Informationen hier.
Ist Clinical Cases in Tropical Medicine E-Book als Online-PDF/ePub verfügbar?
Ja, du hast Zugang zu Clinical Cases in Tropical Medicine E-Book von Camilla Rothe im PDF- und/oder ePub-Format sowie zu anderen beliebten Büchern aus Médecine & Maladies infectieuses. Aus unserem Katalog stehen dir über 1 Million Bücher zur Verfügung.

Information

Verlag
Elsevier
Jahr
2020
ISBN
9780702078804

1: A 20-Year-Old Woman from Sudan With Fever, Haemorrhage and Shock

Daniel G. Bausch

Clinical Presentation

History

A 20-year-old housewife presents to a hospital in northern Uganda with a 2-day history of fever, severe asthenia, chest and abdominal pain, nausea, vomiting, diarrhoea and slight non-productive cough. The patient is a Sudanese refugee living in a camp in the region. She denies any contact with sick people.

Clinical Findings

The patient is prostrate and semiconscious on admission. Vital signs: temperature 39.6°C, (103.3°F) blood pressure 90/60 mmHg, pulse 90 bpm, and respiratory rate 24 cycles per minute. Physical examination revealed abdominal tenderness, especially in the right upper quadrant, hepatosplenomegaly and bleeding from the gums. The lungs were clear. No rash or lymphadenopathy was noted.

Questions

  1. 1. Is the patient’s history and clinical presentation consistent with a haemorrhagic fever (HF) syndrome?
  2. 2. What degree of nursing precautions need to be implemented?

Discussion

This patient was seen during an outbreak of Ebola virus disease in northern Uganda, so the diagnosis was strongly suspected. She was admitted to the isolation ward that had been established as part of the international outbreak response. No clinical laboratory data were available because, for biosafety reasons, such testing was suspended. Although it is a reasonable precaution, the suspension of routine testing often causes difficulty in ruling out the many other febrile syndromes in the differential diagnosis and increases mortality from other non-Ebola disease. Fortunately, many clinical laboratory tests can now be safely performed with point-of-care instruments, often brought into a specialized laboratory in the isolation ward, as long as the laboratory personnel are properly trained and equipped.

Answer to Question 1

Is the Patient’s History and Clinical Presentation Consistent with an HF Syndrome?

The clinical presentation is indeed one of classic viral HF. However, most times the diagnosis is not so easy. Although some patients, such as this one, do progress to the classic syndrome with haemorrhage, multiple organ dysfunction syndrome and shock, haemorrhage is not invariably seen (and may even be noted in only a minority of cases with some virus species), and severe and fatal disease may still occur in its absence. The clinical presentation of viral HF is often very non-specific. Furthermore, haemorrhage may be seen in numerous other syndromes, such as complicated malaria, typhoid fever, bacterial gastroenteritis and leptospirosis, which are the primary differential diagnoses, depending on the region.

Answer to Question 2

What Degree of Nursing Precautions Needs to be Implemented?

The spread of Ebola virus between humans is through direct contact with blood or bodily fluids. Secondary attack rates are generally 15% to 20% during outbreaks in Africa, and much lower if proper universal precautions are maintained. Specialized viral HF precautions and personal protective equipment are warranted when there is a confirmed case or high index of suspicion, such as in this case.

The Case Continued. . .

Intravenous fluids, broad-spectrum antibiotics and analgesics were begun on admission. Nevertheless, the patient’s condition rapidly worsened, with subconjunctival haemorrhage, copious bleeding from the mouth, nose and rectum (Figs. 1.1 and 1.2), dyspnoea and hypothermic shock (temperature 36.0°C, blood pressure = unreadable, pulse 150 bpm, respiratory rate 36 cycles per minute). She became comatose and died approximately 24 hours after admission. Laboratory testing at a specialized laboratory established as part of the outbreak response showed positive ELISA antigen and PCR tests for Ebola virus and a negative result for ELISA IgG antibody, confirming the diagnosis of Ebola virus disease.
Fig. 1.1

Fig. 1.1 Oral bleeding in Ebola virus disease. (Bausch, D.G., 2008. Viral hemorrhagic fevers. In: Schlossberg, D. (Ed.), Clinical Infectious Disease. Cambridge University Press, New York. Used with permission. Photo by Bausch, D.)
Fig. 1.2

Fig. 1.2 Rectal bleeding in Ebola virus disease. (Bausch, D.G., 2008. Viral hemorrhagic fevers. In: Schlossberg, D. (Ed.), Clinical Infectious Disease. Cambridge University Press, New York. Used with permission. Photo by Bausch, D.)
Summary box
Filoviral Diseases
Ebola and Marburg virus disease are the two syndromes caused by filoviruses. Microvascular instability with capillary leak and impaired haemostasis, often including disseminated intravascular coagulation, are the pathogenic hallmarks. There are four known pathogenic species of Ebola and one of Marburg virus, with relatively consistent case fatality associated with each species, ranging from 25% to 85%. Ebola and Marburg diseases are generally indistinguishable, both with non-specific presentations typically including fever, headache, asthenia, myalgias, abdominal pain, nausea, vomiting and diarrhoea. Conjunctival injection and subconjunctival haemorrhage are common. A fleeting maculopapular rash is occasionally seen. Typical laboratory findings include mild lymphopenia and thrombocytopenia, and elevated hepatic transaminases, with AST > ALT. Leucocytosis may be seen in late stages. The differential diagnosis is extremely broad, including almost all febrile diseases common in the tropics.
Ebola and Marburg virus diseases are endemic in sub-Saharan Africa, with Ebola virus typically found in tropical rainforests in the central and western parts of the continent and Marburg virus in the drier forest or savannah in the east. Evidence strongly implicates fruit bats as the filovirus reservoir, especially the Egyptian fruit bat (Rousettus aegyptiacus) as the reservoir for Marburg virus. Human infection likely occurs from inadvertent exposure to infected bat excreta or saliva. Male-to-female sexual transmission may occur months after infection because of the virus’s persistence in the semen, although these events are relatively rare.
Miners, spelunkers, forestry workers and others with exposure in environments typically inhabited by bats are at risk, especially for Marburg virus disease. Non-human primates, especially gorillas and chimpanzees, and other wild animals may serve as intermediate hosts that transmit filoviruses to humans through contact with their blood and bodily fluids, usually associated with hunting and butchering. These wild animals are presumably also infected by exposure to bats and usually develop severe and fatal disease similar to human viral HF. Most outbreaks are thought to result from a single or very few human introductions from a zoonotic source followed by nosocomial amplification through person-to-person transmission in a setting of inadequate universal precautions, usually in rural areas of countries where civil unrest has decimated the healthcare infrastructure.
Because symptoms are generally non-specific and laboratory testing is not widely available, viral HF outbreaks are usually recognized only if a cluster of cases occurs, especially when healthcare workers are involved. Having been into caves or mines, and direct or indirect contact with wild animals or people with suspected viral HF, are key diagnostic clues, but these are not uniformly present. Outside consultation with experts in the field and testing of suspected cases should be rapidly undertaken and public health authorities must be alerted.
Contact tracing should be undertaken to identify all persons with direct unprotected exposure with the case patient, with surveillance of contacts for fever for 21 days (the maximum incubation period for Ebola and Marburg virus diseases). Any contact developing fever or showing other signs of viral HF should immediately be isolated and tested.
Treatment is supportive. Antimalarials and broad-spectrum antibiotics should be given until the diagnosis of viral HF is confirmed. Preliminary results from a clinical trial of experimental compounds conducted during an outbreak in the Democratic Republic of the Congo show very promising results, reducing case fatality to as low as 10% if treatment is administered early in the course of disease. Similarly, a clinical trial of an Ebola vaccine in the Democratic Republic of the Congo and during the massive 2013 to 2016 outbreak in West Africa showed protective efficacy of over 90%.

Further Reading

1 Blumberg L., Enria D., Bausch D.G. Viral haemorrhagic fe...

Inhaltsverzeichnis